Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Atazanavir | Niperotidine can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Cefditoren | The serum concentration of Cefditoren can be decreased when it is combined with Niperotidine. |
| Dabigatran etexilate | Niperotidine can cause a decrease in the absorption of Dabigatran etexilate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Dabrafenib | Niperotidine can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Erlotinib | Niperotidine can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Pazopanib | Niperotidine can cause a decrease in the absorption of Pazopanib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Riociguat | Niperotidine can cause a decrease in the absorption of Riociguat resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Benzylpenicilloyl polylysine | Niperotidine may decrease effectiveness of Benzylpenicilloyl polylysine as a diagnostic agent. |
| Betahistine | The therapeutic efficacy of Betahistine can be decreased when used in combination with Niperotidine. |
| Hyaluronidase (ovine) | The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Niperotidine. |
| Hyaluronidase (human recombinant) | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Niperotidine. |
| Hyaluronidase | The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Niperotidine. |
| Bosutinib | Niperotidine can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Cefpodoxime | Niperotidine can cause a decrease in the absorption of Cefpodoxime resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Cefuroxime | Niperotidine can cause a decrease in the absorption of Cefuroxime resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Dasatinib | Niperotidine can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Delavirdine | Niperotidine can cause a decrease in the absorption of Delavirdine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Dexmethylphenidate | The therapeutic efficacy of Dexmethylphenidate can be decreased when used in combination with Niperotidine. |
| Amprenavir | Niperotidine can cause a decrease in the absorption of Amprenavir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Fosamprenavir | Niperotidine can cause a decrease in the absorption of Fosamprenavir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Gefitinib | Niperotidine can cause a decrease in the absorption of Gefitinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Indinavir | Niperotidine can cause a decrease in the absorption of Indinavir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Itraconazole | Niperotidine can cause a decrease in the absorption of Itraconazole resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ledipasvir | Niperotidine can cause a decrease in the absorption of Ledipasvir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Methylphenidate | The therapeutic efficacy of Methylphenidate can be decreased when used in combination with Niperotidine. |
| Nelfinavir | Niperotidine can cause a decrease in the absorption of Nelfinavir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Nilotinib | Niperotidine can cause a decrease in the absorption of Nilotinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Rilpivirine | Niperotidine can cause a decrease in the absorption of Rilpivirine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Risedronic acid | Niperotidine can cause an increase in the absorption of Risedronic acid resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Saquinavir | Niperotidine can cause an increase in the absorption of Saquinavir resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Levothyroxine | Niperotidine can cause a decrease in the absorption of Levothyroxine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Bisacodyl | The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Niperotidine. |
| Captopril | Niperotidine can cause a decrease in the absorption of Captopril resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Rifampin | Niperotidine can cause a decrease in the absorption of Rifampicin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Memantine | Niperotidine may decrease the excretion rate of Memantine which could result in a higher serum level. |
| Sulpiride | The therapeutic efficacy of Sulpiride can be increased when used in combination with Niperotidine. |
| Mesalazine | Niperotidine can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Mycophenolate mofetil | Niperotidine can cause a decrease in the absorption of Mycophenolate mofetil resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Mycophenolic acid | Niperotidine can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Tolevamer | The therapeutic efficacy of Tolevamer can be decreased when used in combination with Niperotidine. |
| Amphetamine | Amphetamine may decrease the sedative activities of Niperotidine. |
| Phentermine | Phentermine may decrease the sedative activities of Niperotidine. |
| Pseudoephedrine | Pseudoephedrine may decrease the sedative activities of Niperotidine. |
| Benzphetamine | Benzphetamine may decrease the sedative activities of Niperotidine. |
| Diethylpropion | Diethylpropion may decrease the sedative activities of Niperotidine. |
| Lisdexamfetamine | Lisdexamfetamine may decrease the sedative activities of Niperotidine. |
| Mephentermine | Mephentermine may decrease the sedative activities of Niperotidine. |
| MMDA | MMDA may decrease the sedative activities of Niperotidine. |
| Midomafetamine | Midomafetamine may decrease the sedative activities of Niperotidine. |
| 2,5-Dimethoxy-4-ethylamphetamine | 2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Niperotidine. |
| 4-Bromo-2,5-dimethoxyamphetamine | 4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Niperotidine. |
| Tenamfetamine | Tenamfetamine may decrease the sedative activities of Niperotidine. |
| Chlorphentermine | Chlorphentermine may decrease the sedative activities of Niperotidine. |
| Methylenedioxyethamphetamine | Methylenedioxyethamphetamine may decrease the sedative activities of Niperotidine. |
| Dextroamphetamine | Dextroamphetamine may decrease the sedative activities of Niperotidine. |
| Metamfetamine | Metamfetamine may decrease the sedative activities of Niperotidine. |
| Iofetamine I-123 | Iofetamine I-123 may decrease the sedative activities of Niperotidine. |
| Ritobegron | Ritobegron may decrease the sedative activities of Niperotidine. |
| Mephedrone | Mephedrone may decrease the sedative activities of Niperotidine. |
| Methoxyphenamine | Methoxyphenamine may decrease the sedative activities of Niperotidine. |
| Gepefrine | Gepefrine may decrease the sedative activities of Niperotidine. |
| 2,5-Dimethoxy-4-ethylthioamphetamine | 2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Niperotidine. |
| Phendimetrazine | Phendimetrazine may decrease the sedative activities of Niperotidine. |
| Cysteamine | The bioavailability of Cysteamine can be decreased when combined with Niperotidine. |
| Ketoconazole | Niperotidine can cause a decrease in the absorption of Ketoconazole resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Methenamine | The therapeutic efficacy of Methenamine can be decreased when used in combination with Niperotidine. |
| Iron Dextran | Niperotidine can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Iron | Niperotidine can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferric pyrophosphate | Niperotidine can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Prussian blue | Niperotidine can cause a decrease in the absorption of Prussian blue resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Iron sucrose | Niperotidine can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferric ammonium citrate | Niperotidine can cause a decrease in the absorption of Ferric ammonium citrate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferumoxsil | Niperotidine can cause a decrease in the absorption of Ferumoxsil resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferumoxides | Niperotidine can cause a decrease in the absorption of Ferumoxides resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferric sulfate | Niperotidine can cause a decrease in the absorption of Ferric sulfate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferrous bisglycinate | Niperotidine can cause a decrease in the absorption of Ferrous bisglycinate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Gleptoferron | Niperotidine can cause a decrease in the absorption of Gleptoferron resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferric oxide | Niperotidine can cause a decrease in the absorption of Ferric oxide resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Perflubutane | Niperotidine can cause a decrease in the absorption of Perflubutane resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferrous sulfate anhydrous | Niperotidine can cause a decrease in the absorption of Ferrous sulfate anhydrous resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Sodium feredetate | Niperotidine can cause a decrease in the absorption of Sodium feredetate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferric hydroxide | Niperotidine can cause a decrease in the absorption of Ferric hydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferric cation | Niperotidine can cause a decrease in the absorption of Ferric cation resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferrous gluconate | Niperotidine can cause a decrease in the absorption of Ferrous gluconate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferrous succinate | Niperotidine can cause a decrease in the absorption of Ferrous succinate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferrous fumarate | Niperotidine can cause a decrease in the absorption of Ferrous fumarate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Tetraferric tricitrate decahydrate | Niperotidine can cause a decrease in the absorption of Tetraferric tricitrate decahydrate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferric oxyhydroxide | Niperotidine can cause a decrease in the absorption of Ferric oxyhydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferric maltol | Niperotidine can cause a decrease in the absorption of Ferric maltol resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Iron polymaltose | Niperotidine can cause a decrease in the absorption of Iron polymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Fluconazole | Niperotidine can cause a decrease in the absorption of Fluconazole resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Voriconazole | Niperotidine can cause a decrease in the absorption of Voriconazole resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Miconazole | Niperotidine can cause a decrease in the absorption of Miconazole resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Posaconazole | Niperotidine can cause a decrease in the absorption of Posaconazole resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Abafungin | Niperotidine can cause a decrease in the absorption of Abafungin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ravuconazole | Niperotidine can cause a decrease in the absorption of Ravuconazole resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Isavuconazonium | Niperotidine can cause a decrease in the absorption of Isavuconazonium resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Isavuconazole | Niperotidine can cause a decrease in the absorption of Isavuconazole resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Albaconazole | Niperotidine can cause a decrease in the absorption of Albaconazole resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Bifonazole | Niperotidine can cause a decrease in the absorption of Bifonazole resulting in a reduced serum concentration and potentially a decrease in efficacy. |